Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230007/S019

TriClip G5 Delivery System (TCDS0801-NT, TCDS0801-NTW, TCDS0801-XT, TCDS0801-XTW)

ABBOTT MEDICAL · Decision date Feb 25, 2026

FDA DECISIONP230007/S019

What did the FDA approve?

FDA records P230007/S019 as a supplement to PMA P230007, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Feb 25, 2026.

FDA approval order statement

Approval for minor design changes to the clip locking mechanism in the implant and to the delivery system handle of the MitraClip G5 and TriClip G5 Delivery Systems.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Feb 25, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P230007/S019
Regulatory pathway
PMA supplement
Product code
NPS
Decision code
APPR
Decision date
Feb 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Tricuspid valve repair device, percutaneously delivered.

Product code
NPS
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P230007/S016 · Related supplement

    TriClip Delivery System

  2. P230007/S015 · Related supplement

    TriClip G5 Delivery System

  3. P230007/S017 · Related supplement

    TriClip G4 Delivery System; TriClip G5 Delivery System

  4. P230007/S019 received

    Application receipt date recorded by FDA.

  5. P230007/S019 · FDA decision

    Real-Time Process

  6. P230007/S022 · Related supplement

    TriClip Delivery System

Timeline entries are records held by MedtechLedger for P230007. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230007

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA supplementAug 18, 2025FDA
ABBOTT MEDICALPMA supplementAug 20, 2025FDA
ABBOTT MEDICALPMA supplementSep 30, 2025FDA
TriClip G4 SystemP230007/S018
ABBOTT MEDICALPMA supplementOct 17, 2025FDA
TriClip G4 SystemP230007/S020
ABBOTT MEDICALPMA supplementMar 6, 2026FDA
TriClip SystemsP230007/S021
ABBOTT MEDICALPMA supplementMay 14, 2026FDA
ABBOTT MEDICALPMA supplementMay 28, 2026FDA
TriClip SystemsP230007/S023
ABBOTT MEDICALPMA supplementJun 25, 2026FDA

Explore the linked device profile

Other records with product code NPS

Product / regulatory recordCompanyPathwayDecision dateSource
Edwards Lifesciences, LLCPMA supplementOct 20, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
177 County Rd. B E., St. Paul, MN, 55117

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records